References
- Reichard P, Estborn B. Utilization of deoxyribosides in the synthesis of polynucleotides. J Biol Chem 1951;188:839–846.
- Ellims PH, Eng Gan T, Medley G, et al. Prognostic relevance of thymidine kinase in adult non-Hodgkin's lymphoma. Blood 1981;58:926–930.
- Hallek M, Wanders L, Ostwald M, et al. Serum beta(2)-microglobulin and serum thymidine kinase are indepent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma 1996;22:439–447.
- Prochazka V, Faber E, Raida L, et al. High baseline serum thymidine kinase 1 level predicts unfavorable outcome in patients with follicular lymphoma. Leuk Lymphoma 2012;53:1306–1310.
- Suzuki K, Terui Y, Nakano K, et al. High thymidine kinase activity is a strong predictive factor for poor prognosis in peripheral T-cell lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone. Leuk Lymphoma 2012;53:849–854.
- Suzuki K, Terui Y, Yokoyama M, et al. Prognostic value of high thymidine kinase activity in patients with previously untreated diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone. Leuk Lymphoma 2013; 54:2412–2417.
- Schmitz N, Nickelsen M, Ziepert M, et al. Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol 2012;13:1250–1259.
- Papageorgiou SG, Cwynarski K, Kottaridis PD. The role of allogeneic haematopoietic progenitor cell transplantation in patients with diffuse large B-cell non-Hodgkin lymphomas (DLBCL). Bone Marrow Transplant 2013 Jan 14. [Epub ahead of print]
- Dunleavy K, Grant C, Wilson WH. Using biologic predictive factors to direct therapy of diffuse large B-cell lymphoma. Ther Adv Hematol 2013;4:42–57.
- Dasmahapatra G, Patel H, Dent P, et al. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Br J Haematol 2013;161:43–56.
- Yang Y, Shaffer AL 3rd,Emre NC, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012:21:723–737.